v3.21.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
REVENUE
Total Revenues	$ 307,868	$ 123,247	$ 556,077	$ 1,227,594
COST OF GOODS SOLD
Direct costs	157,930	73,113	303,328	950,677
Unallocated manufacturing expenses	503,707	862,280	1,575,422	1,955,494
Total cost of goods sold	661,637	935,393	1,878,750	2,906,171
GROSS LOSS	(353,769)	(812,146)	(1,322,673)	(1,678,577)
OPERATING EXPENSES
Research and development	217,976	381,511	688,230	1,151,524
Sales, general and administrative	957,777	1,266,037	3,326,177	4,173,338
Total operating expenses	1,175,753	1,647,548	4,014,407	5,324,862
OPERATING LOSS	(1,529,522)	(2,459,694)	(5,337,080)	(7,003,439)
OTHER INCOME (EXPENSE)
Interest expense, net	(231,616)	(110,999)	(600,425)	(265,941)
Nonoperating Expense	(4,242)		(4,378)
Total other expense	(235,858)	(110,999)	(604,803)	(265,941)
NET LOSS	$ (1,765,380)	$ (2,570,693)	$ (5,941,883)	$ (7,269,380)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - Basic and diluted (in shares)	3,794,596	4,011,943	3,939,741	3,926,488
NET LOSS PER SHARE - Basic and diluted (in dollars per share)	$ (0.47)	$ (0.64)	$ (1.51)	$ (1.85)
Product sales [Member]
REVENUE
Total Revenues	$ 307,868	$ 123,247	$ 556,077	$ 1,227,594

Cost of material used for good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

XG SCIENCES INC 10-Q